Comparison of Intravitreal Bevacizumab Injection with Combination of Suprachoroidal Triamcinolone Acetonide Along with Intravitreal Bevacizumab Injection in the Treatment of Diabetic Macular Edema in Pseudophakic Patients

Khyber Teaching Hospital

Status and phase: Completed; Phase 4

Conditions: Diabetic Macular Edema (DME)

Treatments: Drug: intravitreal bevacizumab and suprachoroidal triamcinolone acetonide; Drug: Intravitreal Bevacizumab IVB

Study type: Interventional

Funder types: Other

Identifiers

NCT06882551

450/DME/KMC (Other Identifier)

KhyberTeH

Details and patient eligibility

About

Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema

Full description

Patients were included in the study who were pseudophakic with center-involved (sub-foveal) diabetic macular edema. Those patients who had glaucoma history or IOP above 21 mm of Hg, Phakic, corneal opacity, vitreous hemorrhage, proliferative diabetic retinopathy, already received anti-VEGF injections, history of pan-retinal photocoagulation for proliferative diabetic retinopathy.

Enrollment: 82 patients

Sex: All

Ages: 32 to 78 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patients with center involving diabetic macular edema on optical coherence tomography

Exclusion criteria

• Raised intraocular pressure
• History of glaucoma
• Corneal opacity
• Vitreous hemorrhage
• Proliferative diabetic retinopathy
• Anti-VEGF injections in last 3 months
• History of pan-retinal photocoagulation
• Contraindications for anti-VEGF

Trial design

Primary purpose: Treatment

Allocation: Randomized

Interventional model: Parallel Assignment

Masking: None (Open label)

---

82 participants in 2 patient groups

Intravitreal Bevacizumab alone for center involving diabetic macular edema

Experimental group

Description:

Effect of intravitreal Bevacizumab 1.25mg on center involving diabetic macular edema

Treatment:

Drug: Intravitreal Bevacizumab IVB

Suprachoroidal triamcinolone acetonide and intravitreal Bevacizumab

Experimental group

Description:

Combination of suprachoroidal triamcinolone acetonide and intravitreal Bevacizumab for the treatment of diabetic macular edema

Treatment:

Drug: intravitreal bevacizumab and suprachoroidal triamcinolone acetonide